Details for Patent: 8,314,156

Which drugs does patent 8,314,156 protect, and when does it expire?

Patent 8,314,156 protects ABRAXANE and is included in one NDA.

Protection for ABRAXANE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in twenty-one countries.

Summary for Patent: 8,314,156

Title:	Compositions and methods of delivery of pharmacological agents
Abstract:	The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), Trieu; Vuong (Calabasas, CA)
Assignee:	Abraxis BioScience, LLC (Los Angeles, CA)
Application Number:	13/038,287
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,314,156
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,314,156

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005		RX	Yes	Yes					Y

International Family Members for US Patent 8,314,156

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003299590
Brazil	0317134
Canada	2509365
China	102343094